Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.

Dutour, A; Abdesselam, I; Ancel, P; Kober, F; Mrad, G; Darmon, P; Ronsin, O; Pradel, V; Lesavre, N; Martin, J; Jacquier, A; Lefur, Y; Bernard, M; Gaborit, B

Journal article

Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.

Abstract:: Aim

To conduct a prospective randomized trial to investigate the effect of glucagon-like peptide-1 (GLP-1) analogues on ectopic fat stores.

Methods

A total of 44 obese subjects with type 2 diabetes uncontrolled on oral antidiabetic drugs were randomly assigned to receive exenatide or reference treatment according to French guidelines. Epicardial adipose tissue (EAT), myocardial triglyceride content (MTGC), hepatic triglyceride content (HTGC) and pancreatic triglyceride content (PTGC) were assessed 45min after a standardized meal with 3T magnetic resonance imaging and proton magnetic resonance spectroscopy before and after 26weeks of treatment.

Results

The study population had a mean glycated haemoglobin (HbA1c) level of 7.5±0.2% and a mean body mass index of 36.1±1.1 kg/m2. Ninety five percent had hepatic steatosis at baseline (HTGC≥5.6%). Exenatide and reference treatment led to a similar improvement in HbA1c (−0.7±0.3% vs. −0.7±0.4%; p=0.29), whereas significant weight loss was observed only in the exenatide group (−5.5±1.2 kg vs. −0.2±0.8 kg; p=0.001 for the difference between groups). Exenatide induced a significant reduction in EAT (−8.8±2.1%) and HTGC (−23.8±9.5%), compared with the reference treatment (EAT: −1.2±1.6%, p=0.003; HTGC: +12.5±9.6%, p=0.007). No significant difference was observed in other ectopic fat stores, PTGC or MTGC. In the group treated with exenatide, reductions in liver fat and EAT were not associated with homeostatic model assessment of insulin resistance index, adiponectin, HbA1c or fructosamin change, but were significantly related to weight loss (r=0.47, p=0.03, and r=0.50, p=0.018, respectively).

Conclusion

Our data indicate that exenatide is an effective treatment to reduce liver fat content and epicardial fat in obese patients with type 2 diabetes, and these effects are mainly weight loss dependent.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Dutour, A., Abdesselam, I., Ancel, P., Kober, F., Mrad, G., Darmon, P., Ronsin, O., Pradel, V., Lesavre, N., Martin, J., Jacquier, A., Lefur, Y., Bernard, M., & Gaborit, B. (2016). Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes, Obesity & Metabolism, 18(9), 882–891.

MLA Style

Dutour, A, et al. “Exenatide Decreases Liver Fat Content and Epicardial Adipose Tissue in Patients with Obesity and Type 2 Diabetes: a Prospective Randomized Clinical Trial Using Magnetic Resonance Imaging and Spectroscopy.” Diabetes, Obesity & Metabolism, vol. 18, no. 9, 2016, pp. 882–91.

Chicago Style

Dutour, A, I Abdesselam, P Ancel, et al. 2016. “Exenatide Decreases Liver Fat Content and Epicardial Adipose Tissue in Patients with Obesity and Type 2 Diabetes: a Prospective Randomized Clinical Trial Using Magnetic Resonance Imaging and Spectroscopy.” Diabetes, Obesity & Metabolism 18 (9): 882–91.
Print